Who are VRD for first-cycle induction therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Drug: Carfilzomib + Lenalidomide + Dexamethasone, Carfilzomib Lenalidomide Dexamethasone, Bortezomib/Lenalidomide/ Low dose Dex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vrd-for-first-cycle-induction-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

VRD for first-cycle induction therapy — Competitive Intelligence Brief

VRD for first-cycle induction therapy (VRD for first-cycle induction therapy) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proteasome inhibitor + immunomodulatory agent + corticosteroid combination. Area: Oncology.

marketed Proteasome inhibitor + immunomodulatory agent + corticosteroid combination 26S proteasome (bortezomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

VRD for first-cycle induction therapy (VRD for first-cycle induction therapy) — The First Affiliated Hospital of Soochow University. VRD is a combination regimen of bortezomib, lenalidomide, and dexamethasone that targets proteasome inhibition and cereblon-mediated degradation to induce apoptosis in multiple myeloma cells.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
VRD for first-cycle induction therapy TARGET	VRD for first-cycle induction therapy	The First Affiliated Hospital of Soochow University	marketed	Proteasome inhibitor + immunomodulatory agent + corticosteroid combination	26S proteasome (bortezomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
Drug: Carfilzomib + Lenalidomide + Dexamethasone	Drug: Carfilzomib + Lenalidomide + Dexamethasone	Amgen	marketed	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	20S proteasome (carfilzomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
Carfilzomib Lenalidomide Dexamethasone	Carfilzomib Lenalidomide Dexamethasone	European Myeloma Network B.V.	phase 3	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	20S proteasome (carfilzomib); Cereblon/E3 ubiquitin ligase (lenalidomide); Glucocorticoid receptor (dexamethasone)
Bortezomib/Lenalidomide/ Low dose Dex	Bortezomib/Lenalidomide/ Low dose Dex	King Faisal Specialist Hospital & Research Center	phase 3	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	Proteasome (bortezomib); Cereblon (lenalidomide); Glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proteasome inhibitor + immunomodulatory agent + corticosteroid combination class)

The First Affiliated Hospital of Soochow University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VRD for first-cycle induction therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/vrd-for-first-cycle-induction-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab